Shire Loses Fed. Circ. Appeal In Generic Infringement Suit

Law360, Los Angeles (May 9, 2017, 4:41 PM EDT) -- A Federal Circuit panel cleared the way Tuesday for generic-drug maker Zydus to bring its version of Shire PLC's gastrointestinal drug Lialda to market, shooting down Shire's argument that a lower court judge unfairly limited the scope of its patent in a long-running infringement suit.

Shire first accused Cadila Healthcare Ltd. and its U.S. unit Zydus Pharmaceuticals Inc. of infringement nearly seven years ago in Delaware federal court after Zydus filed its abbreviated new drug application for a generic version of Lialda with the U.S. Food and Drug Administration.

After a bench trial, U.S. District Judge Kent. A. Jordan ruled in September that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!